Beyond repressor disruption: Designing activator motifs to boost fetal hemoglobin
Molecular Therapy Nucleic Acids · 2026-12 · 37 (4) · 103147
DOI: 10.1016/j.omtn.2026.103147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Nucleic Acids, 2026-12. Verfasst von Selami Demirci. Beteiligte Einrichtung: Hematology Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20814, USA. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Fetal hemoglobin (HbF) reactivation is now a powerful and clinically validated strategy for sickle cell disease (SCD). Many genome-editing approaches achieve this by disrupting regulatory sequences involved in γ-globin silencing, such as the BCL11A erythroid enhancer. In a recent issue of Molecular Therapy Nucleic Acids, Chalumeau et al.1 replaced the BCL11A binding site in the HBG1/2 promoters with a composite TAL1:GATA1 activating motif rather than only disrupting a repressor site. The edited promoters supported robust γ-globin expression and reduced sickling in erythroid cells derived from SCD hematopoietic stem and progenitor cells (HSPCs).
Autor:innen und Institutionen
- Hematology Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20814, USA.
Zitieren
APA
Demirci, S. (2026). Beyond repressor disruption: Designing activator motifs to boost fetal hemoglobin. Molecular Therapy Nucleic Acids, 37(4), 103147. https://doi.org/10.1016/j.omtn.2026.103147
Vancouver
Demirci S. Beyond repressor disruption: Designing activator motifs to boost fetal hemoglobin. Molecular Therapy Nucleic Acids. 2026;37(4):103147. doi:10.1016/j.omtn.2026.103147
BibTeX
@article{Demirci2026,
author = {Demirci, Selami},
title = {Beyond repressor disruption: Designing activator motifs to boost fetal hemoglobin},
journal = {Molecular Therapy Nucleic Acids},
year = {2026},
volume = {37},
number = {4},
pages = {103147},
doi = {10.1016/j.omtn.2026.103147}
}
EUVIMED